Tradestie Institutional Equity Comparison Engine

ANRO vs MBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANRO Overall Edge

ANRO Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Momentum & Technical, Options & Structure while MBIO counters with relative strength in Growth & Margin. Fundamentally, ANRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ANRO N/M vs MBIO N/M Fwd P/E
Growth & Margin Winner MBIO
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner ANRO
1Y +138.9% vs -68.4% ยท 52W Pos 61% vs 3%
Options & Structure Winner ANRO
BREAKDOWN (8th %ile IV) vs UNCLASSIFIED (N/A IV)
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.12
-8.19% 1D
Market Cap $1.2B
1M Return +23.61%
1Y Return +138.94%
Forward P/E N/M
Unified AI Score
30.5 / 100 SELL
Tech 5.0 Fund 32.0 Flow 65.0 Mom 40.0
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-2.46% 1D
Market Cap $3.2M
1M Return +3.22%
1Y Return -68.44%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ANRO +138.94% MBIO -68.44% Spread: +191.6 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ANRO TTM Op. Margin: 0.0% MBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs MBIO. Trailing 12-month operating profitability (ANRO 0.0% vs MBIO 0.0%) and valuation multiples (ANRO N/M vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ANRO (2) vs MBIO (3)
Institutional Metric ANRO MBIO Criterion Row Winner
Market Capitalization Scale $1.2B $3.2M Larger Scale ANRO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -46.7% -43.1% Higher ROE MBIO
52-Week Range Position Momentum 61% ($11โ€“$37) 3% ($0โ€“$1) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime 1.95ฮฒ ยท 90% Vol 0.68ฮฒ ยท 87% Vol Lower Realized Risk MBIO
Unified Institutional Score Composite Signal 30.5 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite MBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ANRO vs MBIO Buy Guide
ANRO BREAKDOWN
57d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ANRO nor MBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.